Alerts will be sent to your verified email
Verify EmailJBCHEPHARM
JB Chem & Pharma
|
Gland Pharma
|
Wockhardt
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
19.0 . | 366.0 . | n/a |
Number of ANDA's Approved By USFDA
|
17.0 . | 312.0 . | n/a |
Domestic Sales Growth - YoY
|
9.4 % | n/a | 10.6 % |
R&D as a % of Total Sales
|
1.16 % | 4.3 % | 4.2 % |
Financials
|
|||
5 yr Average ROE
|
19.44 % | 14.74 % | -3.81 % |
5yr average Equity Multiplier
|
1.5 | 1.13 | 2.26 |
5yr Average Asset Turnover Ratio
|
0.79 | 0.53 | 0.39 |
5yr Avg Net Profit Margin
|
16.41 % | 24.17 % | -4.46 % |
Price to Book
|
7.97 | 2.72 | 6.76 |
P/E
|
40.02 | 33.87 | 0.0 |
5yr Avg Cash Conversion Cycle
|
19.31 Days | 72.51 Days | -118.47 Days |
Inventory Days
|
51.72 Days | 117.52 Days | 68.12 Days |
Days Receivable
|
63.93 Days | 78.29 Days | 71.63 Days |
Days Payable
|
85.63 Days | 103.04 Days | 260.3 Days |
5yr Average Interest Coverage Ratio
|
65.09 | 205.64 | -0.67 |
5yr Avg ROCE
|
23.24 % | 19.61 % | -1.45 % |
5yr Avg Operating Profit Margin
|
23.72 % | 32.0 % | 3.11 % |
5 yr average Debt to Equity
|
0.08 | 0.01 | 0.71 |
5yr CAGR Net Profit
|
15.23 % | -0.01 % | 46.24 % |
5yr Average Return on Assets
|
13.06 % | 13.18 % | -1.84 % |
Shareholdings
|
|||
Promoter Holding
|
53.66 % | 51.83 % | 49.09 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 18.24 % |
Change in Promoter Holding (3 Yrs)
|
-0.34 % | -6.17 % | -18.04 % |
Change in Mutual Fund Holding (3 Yrs)
|
0.82 % | 19.94 % | 7.53 % |
JB Chem & Pharma
|
Gland Pharma
|
Wockhardt
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Customer Wise Break-Up
|
Customer Wise Break-Up
|
-
|
-
|
Asset Break-Up - Segment Wise
|
Asset Break-Up - Segment Wise
|
-
|
-
|